Apricus Biosciences, Inc.
11975 El Camino Real, Ste 300
San Diego, CA 92130
Phone: (858) 222-8041
http://www.apricusbio.com

COMPANY OVERVIEW

Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has two product candidates currently in development. Vitaros™ is a product candidate in the United States for the treatment of erectile dysfunction, which Apricus in-licensed from Warner Chilcott Inc., now a subsidiary of Allergan. RayVa™ is our product candidate in Phase 2 development for the treatment of circulatory disorder Raynaud's Phenomenon, secondary to scleroderma, which Apricus owns worldwide.

EQUITY OVERVIEW

NSDQ: APRI

Market Cap: $26.0m†

52 Week Range: $0.86 - $4.07†

3 Month Average Volume: 426,406†

Common Shares Outstanding: 15.03m†

Cash Balance: $7.8m††

† As of 9/25/2017 †† As of 6/30/2017. Does not include $3.7m PIPE on 9/13/2017

DRUG DEVELOPMENT PIPELINE



ANALYST COVERAGE

H.C. Wainwright
Roth Capital Partners
See ThruEquity, LLC

POTENTIAL MILESTONES

- Vitaros NDA approval decision on or around February 17, 2018
- RayVa Partnership
- Vitaros Commercialization partnership in H1 2018
  - Allergan Opt-In
  - Out-License
  - Other Strategic Transaction
- Vitaros U.S. launch as early as H2 2018

INVESTOR CONTACT

Matthew Beck
The Trout Group, LLC
(646) 378-2933

INVESTMENT HIGHLIGHTS

Company:
- Specialty pharmaceutical company focused on unmet need in urology and rheumatology
- Novel, capital efficient pipeline with multiple potential value-creating milestones
- Balance sheet supports operations through 2018
- No debt

Vitaros:
- First and only topical treatment for erectile dysfunction
- Rapid onset of action (5-30 minutes)
- Studied in over 3,300 patients with favorable safety and efficacy profile
- Approved in 29 countries outside of US, where it is being commercialized by Ferring and its licensees
- US approval decision expected on or around February 17, 2018
- Allergan holds commercialization option in US
- Company estimates peak US revenue at $350 million
- Broad IP position with potential exclusivity to 2032

RayVa:
- First in class topical treatment for Raynaud's phenomenon secondary to scleroderma
- No approved Raynaud's treatments in US
- Completed Phase 2a clinical trial
- Broad IP position with potential exclusivity to 2032
- May be eligible for priority review in the US